<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:chebi fb="0" ids="114785">Erlotinib</z:chebi> and <z:chebi fb="0" ids="49668">gefitinib</z:chebi>, two inhibitors of the epidermal growth factor receptor (EGFR), can stimulate <z:mpath ids='MPATH_3'>apoptosis</z:mpath> and differentiation of myeloid cell lines that lack EGFR, unveiling a novel, therapeutically exploitable off-target effect of <z:chebi fb="0" ids="38637">tyrosine kinase inhibitors</z:chebi> </plain></SENT>
<SENT sid="1" pm="."><plain>Here, we performed a side-by-side comparison of <z:chebi fb="0" ids="114785">erlotinib</z:chebi> and <z:chebi fb="0" ids="49668">gefitinib</z:chebi> effects on a broad spectrum of malignant myeloid cell lines, as well as on primary myeloblasts freshly purified from the bone marrow of patients with <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) </plain></SENT>
<SENT sid="2" pm="."><plain>Both <z:chebi fb="0" ids="114785">erlotinib</z:chebi> and <z:chebi fb="0" ids="49668">gefitinib</z:chebi> induce <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of a cell line (KG-1) that represents <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, and differentiation in another cell line (P39) derived from a patient with high-risk <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>In this setting, <z:chebi fb="0" ids="114785">erlotinib</z:chebi> was more efficient than <z:chebi fb="0" ids="49668">gefitinib</z:chebi> </plain></SENT>
<SENT sid="4" pm="."><plain><z:chebi fb="0" ids="114785">Erlotinib</z:chebi> and <z:chebi fb="0" ids="49668">gefitinib</z:chebi> were equipotent in inducing <z:mpath ids='MPATH_3'>apoptosis</z:mpath> of primary CD34+ myeloblasts from <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients, yet had no toxic effect on CD34+ progenitor cells from healthy donors </plain></SENT>
<SENT sid="5" pm="."><plain>Although the response of individual <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients in vitro was highly <z:hpo ids='HP_0001425'>heterogeneous</z:hpo>, the pro-apoptotic effects of <z:chebi fb="0" ids="114785">erlotinib</z:chebi> and <z:chebi fb="0" ids="49668">gefitinib</z:chebi> correlated significantly </plain></SENT>
<SENT sid="6" pm="."><plain>These results suggest that <z:chebi fb="0" ids="114785">erlotinib</z:chebi> and <z:chebi fb="0" ids="49668">gefitinib</z:chebi> share a mechanistically related off-target effect that may be taken advantage of for the therapy of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
</text></document>